166 related articles for article (PubMed ID: 37559042)
1. Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
Yigit V; Kalender S; Cetinturk I
Cost Eff Resour Alloc; 2023 Aug; 21(1):51. PubMed ID: 37559042
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price.
Sinha P; Barocas JA
Alzheimers Dement (N Y); 2022; 8(1):e12256. PubMed ID: 35282659
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease.
Whittington MD; Campbell JD; Rind D; Fluetsch N; Lin GA; Pearson SD
Neurology; 2022 Mar; 98(9):e968-e977. PubMed ID: 35022306
[TBL] [Abstract][Full Text] [Related]
5. Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
Neurol Ther; 2021 Dec; 10(2):919-940. PubMed ID: 34426940
[TBL] [Abstract][Full Text] [Related]
6. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
Connock M; Burls A; Frew E; Fry-Smith A; Juarez-Garcia A; McCabe C; Wailoo A; Abrams K; Cooper N; Sutton A; O'Hagan A; Moore D
Health Technol Assess; 2006 Jul; 10(24):iii-iv, ix-136. PubMed ID: 16796930
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease.
Salcedo J; Bulovic J; Young CM
Sci Rep; 2021 May; 11(1):10838. PubMed ID: 34035408
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
18. Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease.
Boustani M; Doty EG; Garrison LP; Smolen LJ; Belger M; Klein TM; Murphy DR; Burge R; Wall JK; Johnston JA
Clin Ther; 2022 Nov; 44(11):1449-1462. PubMed ID: 36210219
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
